Johnson & Johnson
📊 Market Data
📈 Income Statement (SEC Verified)
| Metric | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.45B | $22.47B | $88.82B | $21.89B | $23.74B | $23.99B | $94.19B | $24.06B |
| Net Income | $4.69B | $2.69B | $14.07B | $11.00B | $5.54B | $5.15B | $26.80B | $5.24B |
| EPS (Diluted) | $1.93 | $1.11 | $5.79 | $4.54 | $2.29 | $2.12 | $11.03 | $2.14 |
💹 Profitability & Margins
🏦 Balance Sheet
💸 Cash Flow Statement
🎯 Analyst Ratings & Price Targets
Consensus Recommendation
BuyBased on 24 analyst opinions
| Target High | $285.00 |
| Target Mean | $252.96 |
| Target Low | $155.00 |
| Current Price | $228.92 |
| Upside Potential | +10.5% |
🏢 Company Information
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospita...
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Employees | 138,200 |
| Headquarters | New Brunswick, NJ, United States |
| Website | https://www.jnj.com |
| Exchange | NYQ |
| Currency | USD |
| Shares Outstanding | 2.41B |
| Insider Ownership | 0.1% |
| Institutional Ownership | 76.8% |
| EPS (TTM) | 8.63 |
| EPS (Forward) | 12.71 |
| PEG Ratio | 2.98 |
| Next Earnings Date | 2026-07-15 |